Acro Biomedical Co., Ltd. was established in 2014, headquartered in the Southern Taiwan Science Park, and went public on Taiwan’s OTC market in 2021 with the stock code 6748. As a leading enterprise in Taiwan’s regenerative medicine sector, Acro Biomedical focuses on developing advanced medical devices centered on natural collagen.
 

The company pioneered the world’s first "supercritical carbon dioxide decellularization technology," which thoroughly removes cells and impurities from animal tissues while fully preserving the triple-helix structure of collagen. This innovation significantly reduces risks of immune rejection and allergic reactions, creating an optimal biological environment for human tissue repair and regeneration.
 

Acro Biomedical’s product portfolio spans ophthalmology, orthopedics, dentistry, neurosurgery, plastic surgery, and wound care, with 95 global patents to date, demonstrating exceptional clinical value. Notably, its "ABCcolla® Collagen Corneal Matrix," certified by Taiwan’s Ministry of Health and Welfare in 2025, is the world’s first animal collagen corneal substitute manufactured using supercritical carbon dioxide decellularization technology. It is protected by patents in fifteen countries and has received the National Drug and Medical Technology Development Award, setting a new benchmark in corneal repair and reconstruction.
 

Rooted in Taiwan and reaching out globally, Acro Biomedical actively advances multinational clinical trials and medical device certifications. It has forged deep strategic alliances with international medical partners and industrial groups. More than a beacon of technological innovation, Acro Biomedical is a compassionate force dedicated to revitalizing and enhancing the value of life, we continue to make the impossible possible.